Two transgenic mouse models for beta subunit components of succinate-CoA ligase yielding pleiotropic metabolic alterations by Kacsó, Gergely et al.
Research Article
Two transgenic mouse models for β-subunit
components of succinate-CoA ligase yielding
pleiotropic metabolic alterations
Gergely Kacso1,2, Dora Ravasz1,2, Judit Doczi1,2, Beáta Németh1,2, Ory Madgar1,2, Ann Saada3, Polina Ilin3,
Chaya Miller3, Elsebet Ostergaard4, Iordan Iordanov1,5, Daniel Adams1,2, Zsuzsanna Vargedo1,2,
Masatake Araki6, Kimi Araki6, Mai Nakahara6, Haruka Ito6, Aniko Gál7, Mária J. Molnár7, Zsolt Nagy8,
Attila Patocs8, Vera Adam-Vizi1,9 and Christos Chinopoulos1,2
1Department of Medical Biochemistry, Semmelweis University, Tuzolto Street 37-47, Budapest 1094, Hungary; 2MTA-SE Lendület Neurobiochemistry Research Group, Budapest
1094, Hungary; 3Monique and Jacques Roboh Department of Genetic Research and the Department of Genetic and Metabolic Diseases, Hadassah-Hebrew University Medical
Center, Jerusalem 91120, Israel; 4Department of Clinical Genetics, Copenhagen University Hospital Rigshospitalet, Copenhagen 2100, Denmark; 5MTA-SE Lendület Ion Channel
Research Group, Budapest 1094, Hungary; 6Institute of Resource Development and Analysis, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto 860-0811, Japan;
7Institute of Genomic Medicine and Rare Disorders, Semmelweis University, Budapest 1083, Hungary; 8MTA-SE Lendület Hereditary Endocrine Tumours Research Group,
Budapest 1088, Hungary; and 9MTA-SE Laboratory for Neurobiochemistry, Budapest 1094, Hungary
Correspondence: Christos Chinopoulos (chinopoulos.christos@eok.sote.hu)
Succinate-CoA ligase (SUCL) is a heterodimer enzyme composed of Suclg1 α-subunit
and a substrate-speciﬁc Sucla2 or Suclg2 β-subunit yielding ATP or GTP, respectively. In
humans, the deﬁciency of this enzyme leads to encephalomyopathy with or without
methylmalonyl aciduria, in addition to resulting in mitochondrial DNA depletion. We gen-
erated mice lacking either one Sucla2 or Suclg2 allele. Sucla2 heterozygote mice exhib-
ited tissue- and age-dependent decreases in Sucla2 expression associated with
decreases in ATP-forming activity, but rebound increases in cardiac Suclg2 expression
and GTP-forming activity. Bioenergetic parameters including substrate-level phosphoryl-
ation (SLP) were not different between wild-type and Sucla2 heterozygote mice unless a
submaximal pharmacological inhibition of SUCL was concomitantly present. mtDNA con-
tents were moderately decreased, but blood carnitine esters were signiﬁcantly elevated.
Suclg2 heterozygote mice exhibited decreases in Suclg2 expression but no rebound
increases in Sucla2 expression or changes in bioenergetic parameters. Surprisingly, dele-
tion of one Suclg2 allele in Sucla2 heterozygote mice still led to a rebound but protracted
increase in Suclg2 expression, yielding double heterozygote mice with no alterations in
GTP-forming activity or SLP, but more pronounced changes in mtDNA content and blood
carnitine esters, and an increase in succinate dehydrogenase activity. We conclude that a
partial reduction in Sucla2 elicits rebound increases in Suclg2 expression, which is sufﬁ-
ciently dominant to overcome even a concomitant deletion of one Suclg2 allele, pleiotro-
pically affecting metabolic pathways associated with SUCL. These results as well as the
availability of the transgenic mouse colonies will be of value in understanding SUCL
deﬁciency.
Introduction
Succinate-CoA ligase (SUCL), also known as succinyl coenzyme A synthetase, or succinate thiokinase
is a heterodimer enzyme composed of an invariant α-subunit encoded by SUCLG1 and a substrate-
speciﬁc β-subunit encoded by either SUCLA2 or SUCLG2. This dimer combination results in either an
ATP-forming (EC 6.2.1.5) or a GTP-forming SUCL (EC 6.2.1.4). ΔG of either reaction is ∼0.07 kJ/
mol and therefore, reversible [42]. SUCL is located in the mitochondrial matrix catalyzing the
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conversion of succinyl-CoA and ADP (or GDP) to CoASH, succinate and ATP (or GTP) [30]. As such, it is at
the intersection of several metabolic pathways [71]: (i) it is part of the citric acid cycle, a major metabolic hub
for the interconversion of many metabolites; (ii) when SUCL proceeds in the direction towards succinyl-CoA,
this product may follow heme metabolism [39]; (iii) in extrahepatic tissues, succinyl-CoA will also participate
in the metabolism of ketone bodies [21]; (iv) the reaction proceeding towards ATP formation termed ‘substrate-
level phosphorylation’ (SLP) can yield high-energy phosphates in the absence of oxygen [11,13,35], whereas
GTP-forming SUCL may support ATP formation through concerted action with a mitochondrial nucleotide
diphosphate kinase which complexates with either ATP- or GTP-forming SUCL [31,32,38]; (v) exactly because
of the association of SUCL with the nucleotide diphosphate kinase, SUCL is important in maintaining mtDNA
content through provision of phosphorylated deoxyribonucleotides [69]; (vi) succinyl-CoA is the entry point to
the citric acid cycle in the catabolism of certain biomolecules (methionine, threonine, isoleucine, valine, propi-
onate, odd chain fatty acids and cholesterol) through propionyl → methylmalonyl → to succinyl-CoA mediated
by the sequential actions of propionyl-CoA carboxylase and methylmalonyl-CoA mutase [53]; (vii) in turn,
increases in propionyl-CoA and methylmalonyl-CoA may cause secondary metabolic aberrations due to their
ability to inhibit steps in urea cycle, gluconeogenesis and the glycine cleavage system [65]; (viii) in specialized
cells of the brain, succinate is the entry point to the citric acid cycle of the ‘GABA shunt’ from succinate semi-
aldehyde, a metabolite which is also in equilibrium with γ-hydroxybutyric acid [28,55,59] and (ix) in cells of
macrophage lineage, SUCL metabolizes endogenously produced itaconate to itaconyl-CoA [51]. Furthermore,
succinyl-CoA has been recently reported to serve as a cofactor for lysine succinylation, a wide-spread posttran-
slational modiﬁcation [77], and succinate to be a metabolic signal in inﬂammation [48,70]. Finally, succinate
has been branded as an ‘oncometabolite’ linking the citric acid cycle to hypoxia and oncogenesis [11,66,67].
In view of the involvement of SUCL in all of the above, it is not surprising that its deﬁciency leads to pleio-
tropic pathology, which is also inﬂuenced by the tissue-speciﬁc expression of its subunits: SUCLA2 is strongly
expressed in skeletal muscle, brain and heart, whereas SUCLG2 is barely detected in brain and muscle, but
robustly expressed in liver and kidney [40]. Furthermore, in the human brain, SUCLA2 is exclusively expressed
in the neurons, whereas SUCLG2 is only found in cells forming the microvasculature [16,17].
To date, 51 patients have been reported with SUCLA2 deﬁciency [6,7,20,24,29,41,44,46,49,50,52,54], and 21
patients with SUCLG1 deﬁciency, due to different mutations [7]. Patients with SUCLG1 mutations may have
an extremely severe phenotype with antenatal manifestations of the disorder, severe acidosis with lactic aciduria
in the ﬁrst day of life and death within 2–4 days [53] or a phenotype similar to those of patients with SUCLA2
mutations. Mutations in the SUCLG2 gene have not been reported so far and may be incompatible with life.
SUCLA2 deﬁciency (MIM ID#612073) has an incidence of 1 in 1700 in the Faroe Islands due to a founder
effect and a carrier frequency of 1 in 33 [54]. More recently, evidence of two founder mutations in the
Scandinavian population has also been put forward [7]. The symptoms comprise hypotonia, muscle atrophy,
hyperkinesia, severe hearing impairment and postnatal growth retardation. Neuroimaging ﬁndings comprise
demyelination, central and cortical atrophy including atrophy of the basal ganglia [6,54]. Some of the patients
fulﬁl the criteria for Leigh syndrome [53]. Urine and plasma methylmalonic acid, C3-carnitine and
C4-dicarboxylic carnitine (the latter likely to be a mixture of succinyl and methylmalonyl carnitine ester) are
elevated [53,54], while there are no abnormalities related to liver functions. Median survival is 20 years [7]; the
longest documented survival is 45 years [49]. It is being hypothesized that patients with missense mutations in
SUCLA2 (or SUCLG1) may exhibit some residual SUCL activity that is associated with longer survivals;
however, given the small number of patients and the lack of expression studies providing direct experimental
evidence of residual activity, such postulations must be interpreted cautiously [7]. Heterozygous relatives of
patients with SUCLA2 deﬁciency are asymptomatic [53,54].
Given the role of SUCL in maintaining mtDNA content, SUCLA2 deﬁciency patients suffer from mtDNA
depletion in muscle [50,53,54]. Data from heart and brain biopsies are not available. mtDNA depletion has also
been reported in ﬁbroblasts but only from some patients [6], or only after serum deprivation [47]. mtDNA deple-
tion would inﬂuence many targets in mitochondria, including the electron transport complexes of the respiratory
chain creating a bioenergetic insufﬁciency that could in turn impair energy-dependent mechanisms. Indeed,
respiratory chain enzyme analysis show decreased complex I, III and IV activity, whereas complex II, which is
encoded exclusively by nDNA genes, shows normal activity [7,54]. There are no data available regarding ETC
activities from brain tissue. In ﬁbroblasts, a slightly decreased complex IV activity has been reported [54].
Here, we generated transgenic mice lacking either one Sucla2 or one Suclg2 allele. Homozygous knockout
mice for either gene were never born. We quantitated the expression of SUCL subunits in mitochondria
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isolated from brains, hearts and livers of 3-, 6- and 12-month-old wild-type (WT) and heterozygote mice. In
the tissues of Sucla2 heterozygote mice, we investigated respiration rates and membrane potential (ΔΨm) for
an array of mitochondrial substrates and various metabolic states, complex I, II, II/III and IV activities, as well
as SLP during respiratory inhibition or true anoxia. SLP was further investigated during submaximal inhibition
of SUCL by either itaconate or KM4549SC. We also compared mtDNA content, ATP-forming and
GTP-forming SUCL activities, and blood levels of 20 carnitine esters. Furthermore, we cross-bred Sucla2+/−
with Suclg2+/− mice, yielding double heterozygote Sucla2+/−/Suclg2+/− mice, and investigated the expression
of g1, g2 and a2 subunits, mtDNA content, blood carnitine esters and bioenergetic parameters.
Our results show that, in Sucla2 heterozygote mice, there is a rebound increase in Suclg2 expression asso-
ciated with mostly unaffected bioenergetic parameters, while mtDNA contents are moderately decreased in
some organs, and blood carnitine levels are elevated. The rebound increase in Suclg2 expression due to deletion
of one Sucla2 allele was so dominant that it was even observed — albeit to a moderate extent — in double het-
erozygote Sucla2+/−/Suclg2+/− mice. Results obtained from embryonic tissues of Sucla2−/− mice have been
published in ref. [18] and are discussed in relation to the results obtained here.
Experimental procedures
Animals
Mice were of either 129/SvEv (Sucla2 heterozygote strain) or C57Bl/6N (Suclg2 heterozygote strain) back-
ground. The animals used in our study were of either sex and of 3, 6 or 12 months of age. Mice were housed
in a room maintained at 20–22°C on a 12-h light–dark cycle with food and water available ad libitum. All
experiments were approved by the Animal Care and Use Committee of the Semmelweis University (Egyetemi
Állatkísérleti Bizottság) and the EU Directive 2010/63/EU for animal experiments. Sucla2 heterozygous
mice were generated by Texas A&M Institute for Genomic Medicine (TIGM). Suclg2 heterozygote mice
[B6-Suclg2Gt(pU-21KBW)131Card] were generated at CARD, Kumamoto University, Japan. For further details
regarding the generation of these two mouse colonies, see the Results section. Neither Sucla2 −/− nor Suclg2 −/−
mice were ever born from mating heterozygous mice, suggesting that the complete absence of either gene is
incompatible with life in mice, and as also reported in ref. [18]. By mating Sucla2 heterozygous mice with
Suclg2 heterozygous mice, double transgenic (Sucla2+/−/Suclg2+/−) mice were born and viable.
Isolation of mitochondria
Isolation of mitochondria from mouse liver, heart and brain: liver and heart mitochondria from all animals
were isolated as described in ref. [72], with the modiﬁcations described in refs [13] and [15]. Nonsynaptic
brain mitochondria were isolated on a Percoll gradient as described previously [68], with minor modiﬁcations
detailed in ref. [14]. Protein concentration was determined using the bicinchoninic acid assay and calibrated
using bovine serum standards using a Tecan Inﬁnite® 200 PRO series plate reader (Tecan Deutschland GmbH,
Crailsheim, Germany). Yields were typically 0.2 ml of ∼20 mg/ml per two brains; for liver, yields were typically
0.7 ml of ∼70 mg/ml per two livers, and for heart mitochondria, yields were typically 0.1 ml of ∼15 mg/ml per
two hearts.
Determination of membrane potential in isolated liver mitochondria
ΔΨm of isolated mitochondria [0.5–1 mg — depending on the tissue of origin — per two ml of medium con-
taining (in mM): KCl 8, K-gluconate 110, NaCl 10, HEPES 10, KH2PO4 10, EGTA 0.005, mannitol 10, MgCl2
1, substrates as indicated in the ﬁgure legends, 0.5 mg/ml bovine serum albumin (fatty acid-free), pH 7.25 and
5 mM safranin O] was estimated ﬂuorimetrically with safranin O [1]. Traces obtained from mitochondria were
calibrated to millivolts as described in ref. [13]. Fluorescence was recorded in a Hitachi F-7000 spectroﬂuori-
meter (Hitachi High Technologies, Maidenhead, UK) at a 5-Hz acquisition rate using 495- and 585-nm excita-
tion and emission wavelengths, respectively, or at a 1-Hz rate using the O2k-Fluorescence LED2-Module of the
Oxygraph-2k (Oroboros Instruments, Innsbruck, Austria) equipped with an LED exhibiting a wavelength
maximum of 465 ± 25 nm (current for light intensity adjusted to 2 mA, i.e. level ‘4’) and an <505 nm shortpass
excitation ﬁlter (dye-based, ﬁlter set ‘Safranin’). Emitted light was detected by a photodiode (range of sensitiv-
ity: 350–700 nm), through an >560 nm longpass emission ﬁlter (dye-based). Experiments were performed at
37°C. Safranin O is known to exert adverse effects on mitochondria if used at sufﬁciently high concentrations
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(i.e. above 5 μM, discussed in ref. [36]). However, for optimal conversion of the ﬂuorescence signal to ΔΨm, a
concentration of 5 μM safranin O is required, even if it leads to diminution of the respiratory control ratio by
approximately one unit (not shown). Furthermore, the nonspeciﬁc binding component of safranin O to mito-
chondria (dictated by the mitochondria/safranin O ratio) was within 10% of the total safranin O ﬂuorescence
signal, estimated by the increase in ﬂuorescence caused by the addition of a detergent to completely depolarized
mitochondria (not shown). As such, it was accounted for, during the calibration of the ﬂuorescence signal to
ΔΨm.
Mitochondrial respiration
Oxygen consumption was estimated polarographically using an Oxygraph-2k. Depending on the tissue of
origin, mitochondria (0.5–1 mg) were suspended in 2 ml of incubation medium, the composition of which was
identical with that for ΔΨm determination. Experiments were performed at 37°C. Oxygen concentration and
oxygen ﬂux (pmol s−1 mg−1; negative time derivative of oxygen concentration, divided by mitochondrial mass
per volume and corrected for instrumental background oxygen ﬂux arising from oxygen consumption of the
oxygen sensor and back-diffusion into the chamber) were recorded using DatLab software (Oroboros
Instruments).
Cell cultures
Fibroblast cultures from skin biopsies from the patient with no SUCLA2 expression and a control subject were
prepared. Cells were grown on poly-L-ornithine-coated ﬂasks for 5–7 days in RPMI1640 medium (GIBCO, Life
Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum and 2 mM glutamine and kept
at 37°C in 5% CO2. The medium was also supplemented with penicillin, streptomycin and amphotericin
(Sigma-Aldrich, St. Louis, MO, USA).
Mitochondrial membrane potential determination in in situ mitochondria of
permeabilized ﬁbroblast cells
Mitochondrial membrane potential (ΔΨm) was estimated using ﬂuorescence quenching of the cationic dye saf-
ranin O due to its accumulation inside energized mitochondria [1]. Fibroblasts were harvested by trypsiniza-
tion, permeabilized as detailed in ref. [33] and suspended in a medium identical with that as for ΔΨm
measurements in isolated mitochondria. Substrates were 5 mM glutamate and 5 mM malate. Fluorescence was
recorded in a Tecan Inﬁnite® 200 PRO series plate reader using 495 and 585 nm excitation and emission wave-
lengths, respectively. Experiments were performed at 37°C.
Western blot analysis
Isolated mitochondria were solubilized in RIPA buffer containing a cocktail of protease inhibitors (Protease
Inhibitor Cocktail Set I, Merck Millipore, Billerica, MA, USA) and frozen at −80°C for further analysis. Frozen
pellets were thawed on ice, and their protein concentration was determined using the bicinchoninic acid assay as
detailed above, loaded at a concentration of 3.75 mg per well on the gels and separated by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS–PAGE). Separated proteins were transferred onto a
methanol-activated polyvinylidene diﬂuoride membrane. Immunoblotting was performed as recommended by the
manufacturers of the antibodies. Rabbit polyclonals anti-SUCLG1, anti-SUCLG2, anti-voltage-dependent anion
channel 1 (VDAC1; Abcam, Cambridge, UK), and anti-SUCLA2 (Proteintech Europe Ltd, Manchester, UK)
primary antibodies were used at titers of 1:5000. Immunoreactivity was detected using the appropriate peroxidase-
linked secondary antibody (1:5000, donkey anti-rabbit Jackson Immunochemicals Europe Ltd, Cambridgeshire,
UK) and enhanced chemiluminescence detection reagent (ECL system; Amersham Biosciences GE Healthcare
Europe GmbH, Vienna, Austria). Densitometric analysis of the bands was performed in Fiji [64].
mtDNA content
Total DNA was isolated from four pooled tissues from each mouse group using the QIAamp DNA Mini Kit
(QIAGEN) following the manufacturer’s instructions. Relative mtDNA content was quantiﬁed in triplicate by
real-time PCR using primers for cox1 (forward primer 50-TGCTAGCCGCAGGCATTA C-30; reverse primer
50-GGGTGCCCAAAGAATCAGAAC-30) and normalized against the nuclear-encoded actinB gene (forward
primer 50-GGAAAAGAGCCTCAGGGCAT-30, reverse primer 50-GAAGAGCTATGAGCTGCCTGA-30), as
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previously described [76]. DNA was ampliﬁed in an ABI 7900 system as follows: 95°C for 10 min followed by
45 cycles of a two-stage temperature proﬁle of 95°C for 15 s and 60°C for 1 min.
Protein puriﬁcation
The gene sequences for mature human SUCLG1 (residues 29–333, ∼33.2 kDa, GenBank: CAG33420.1) and
mature human SUCLG2 (residues 39–432, ∼43.6 kDa, GenBank: AAH68602.1) were sequence-optimized for
expression in Escherichia coli, synthesized, incorporated in pJ411 plasmids bearing kanamycin resistance, and
sequence-veriﬁed (DNA2.0, Newark, CA, USA). The native protein sequence in each case was supplemented
with a C-terminal hexahistidine tag (GSHHHHHH). Each pJ411-SUCLG1/2 plasmid was transfected into indu-
cible E. coli BL21 (DE3) strain and the bacteria were grown in Luria-Bertani medium at 37°C. Protein expres-
sion was induced with 1 mM isopropyl β-D-1-thiogalactopyranoside for 3 h. The collected bacteria were
sonicated in 10 ml of lysis buffer [25 mM Tris (pH 8.5), 150 mM NaCl, 0.5 mg/ml lysozyme, 0.2% Triton
X-100] per gram of wet pellet. Both proteins formed inclusion bodies when overexpressed, with minimal or no
presence in the soluble fraction of the lysate. The proteins were puriﬁed in their unfolded state (7 M urea and
200 mM NaCl) with afﬁnity chromatography, after binding to Ni-Sepharose™ 6 Fast Flow resin (GE
Healthcare). The eluates were diluted 15-fold in 20 mM Tris (pH 8.5) and 100 mM NaCl, the precipitated
protein was removed and the supernatants were dialyzed against the same buffer. The purity of the two pro-
teins was assessed with SDS–PAGE and the ﬁnal protein concentrations were estimated using the bicinchoninic
acid assay as detailed above. The protein stocks were aliquoted, ﬂash-frozen in liquid nitrogen and stored at −80°C.
Electron transport chain complex and citrate synthase activity assays
Enzymatic activities of rotenone-sensitive NADH CoQ reductase (complex I), succinate cytochrome c reductase
(complex II/III), succinate dehydrogenase (complex II), cytochrome c oxidase (complex IV) and citrate synthase
(CS), a mitochondrial marker enzyme, were determined in isolated mitochondria as we have previously
described [58,60].
Determination of SUCL activity
ATP- and GTP-forming SUCL activity in isolated mitochondria was determined at 30°C, as described in ref.
[3], with the modiﬁcations detailed in ref. [40]. Mitochondria (0.25 mg) were added in an assay mixture (2 ml)
containing 20 mM potassium phosphate, pH 7.2, 10 mM MgCl2 and 2 mM ADP or GDP. The reactions were
initiated by adding 0.2 mM succinyl-CoA and 0.2 mM DTNB [5,50-dithiobis(2-nitrobenzoic acid)] in quick suc-
cession. The molar extinction coefﬁcient value at 412 nm for the 2-nitro-5-thiobenzoate anion formed upon
reaction of DTNB with CoASH was considered as 13 600 M−1 cm−1. Rates of 2-nitro-5-thiobenzoate formation
were followed spectrophotometrically during constant stirring.
Determination of acylcarnitines
Multiple reaction monitoring transitions of butyl ester derivatives of acylcarnitines from dry bloodspots and
stable isotope internal standards were analyzed by electrospray ionization tandem mass spectrometry (MS–MS)
using a Waters Alliance 2795 separations module coupled to a Waters Micromass quarto micro API mass spec-
trometer monitoring for acylcarnitines (Milford, MA, USA), as described in ref. [57].
Determination of Sucla2 mRNA by quantitative real-time PCR
mRNA coding for Sucla2 was quantiﬁed by qPCR in two different laboratories using two different ‘housekeep-
ing’ mRNAs for normalization, β-actin or proteasome 26S subunit, ATPase 4 (Psmc4). In both cases, total
RNA was isolated from the organs (livers, hearts and brains) of at least four mice per age group and genotype
(WT or Sucla2+/−) with the RNeasy Micro Kit (Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. RNA (1 mg) was reverse-transcribed with the QuantiTect Reverse Transcription Kit (Qiagen).
Subsequently, quantitative real-time PCR was carried out using predesigned TaqMan Gene Expression Assays
(Thermo Fisher Scientiﬁc, Waltham, MA, USA): Sucla2 (Mm01310541_m1) and Actb (Mm00607939_s1).
Real-time reaction was performed on a QuantStudio 7 Flex Real-Time PCR system (Applied Biosystems, Life
Technologies, Carlsbad, CA, USA) according to the manufacturer’s protocol. Gene expression level was normal-
ized to β-actin. Fold change was calculated using the 2-ΔΔCt method [8]. Alternatively, expression level of
Sucla2 mRNA was determined by real-time PCR using the TaqMan Gene Expression assay kit and 7500
Real-Time PCR System (Applied Biosystems), using the TaqMan Gene Expression Assays, XS, Sucla2
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(AB, 4331182, FAM/MGB-NFQ) kit. Measured values were normalized by using the TaqMan Gene Expression
Controls, Psmc4 mouse (AB, 4448489, VIC-MGB) kit, as recommended by Applied Biosystems for standard
gene expression experiments because of their design criteria.
Statistics
Data are presented as averages ± SEM or SD where indicated. Signiﬁcant differences between two groups were
evaluated by Student’s t-test; signiﬁcant differences between three or more groups were evaluated by one-way
analysis of variance followed by Tukey’s or Dunnett’s post hoc analysis. A value of P < 0.05 was considered statis-
tically signiﬁcant. *P < 0.05, **P < 0.01 and ***P < 0.001. If normality test failed, ANOVA on ranks was per-
formed. Wherever single graphs are presented, they are representative of at least three independent experiments.
Reagents
Standard laboratory chemicals, enzyme substrates and itaconic acid were from Sigma-Aldrich. SF 6847 was
from Enzo Life Sciences (ELS AG, Lausen, Switzerland). Carboxyatractyloside (cATR) was from Merck (Merck
KGaA, Darmstadt, Germany). KM4549SC (LY266500) was from Molport (SIA Molport, Riga, Latvia).
Mitochondrial substrate stock solutions were dissolved in bi-distilled water and titrated to pH 7.0 with KOH.
ADP was purchased as a K+ salt of the highest purity available (Merck) and titrated to pH 6.9. TaqMan Gene
Expression Assays, XS, Suclg2 (AB, 4448892, FAM/MGB-NFQ) kit and Actb (AB, 4448489, VIC-MGB) kit
were from Thermo Fisher Scientiﬁc. qPCR mix was qPCRBIO SyGreen Mix Hi-Rox (PCR Biosystems).
Results
Generation of Sucla2 mutant mice, Sucla2 mRNA quantiﬁcation, SUCL subunit
expression and enzymatic activities in WT vs. Sucla2+/− mice
Mutant Sucla2 mice were generated using a gene-trapping technique [26]. Mice (strain C57BL/6N) were cloned
from an ES cell line (IST10208H1; TIGM). The ES cell clone contained a retroviral insertion in the Sucla2 gene
(intron 4) identiﬁed from the TIGM gene trap database and was microinjected into C57BL/6 albino host blasto-
cysts to generate germline chimaeras using standard procedures. The retroviral OmniBank Vector 76 contained a
splice acceptor (Figure 1A) followed by a selectable neomycin resistance marker/LacZ reporter fusion (β-Geo) for
identiﬁcation of successful gene trap events further followed by a polyadenylation signal. Insertion of the retroviral
vector into the Sucla2 gene led to the splicing of the endogenous upstream exons into this cassette to produce a
fusion that leads to termination of further transcription of the endogenous Sucla2 exons downstream of the inser-
tion. Chimaeric males were bred to 129/SvEv females for germline transmission of the mutant Sucla2 allele.
Total RNA was isolated from the livers, hearts and brains of 3-, 6- and 12-month-old WT and Sucla2+/−
mice (four animals per group), and Sucla2 mRNA was quantiﬁed by qPCR, ratioed to β-actin (Figure 1B) or
Psmc4 expression (Figure 1C). As shown in Figures 1B,C, mRNA coding for Sucla2 was signiﬁcantly decreased
(26–71%) in the tissues obtained from Sucla2+/− mice, compared with those obtained from WT littermates.
These results are in accordance with those obtained from immunodetection of Sucla2 subunit by Western blot-
ting. These data are depicted in Figure 2. Mitochondria were prepared from the livers, hearts and brains of 3-,
6-, and 12-month-old WT and Sucla2+/− mice and SUCLG1, SUCLA2, SUCLG2 and VDAC1 were immuno-
detected by Western blotting. Only 3.75 mg of puriﬁed mitochondria (pooled from mitochondria obtained
from eight organs per group) were loaded on each gel lane so as not to saturate the ﬁnal enhanced chemilu-
minescence signals (see the ‘Experimental Procedures’ section). Scanned images of representative Western blots
are shown in Figure 2A–C. As shown in the ﬁrst two lanes of the left topmost panel in Figure 2A, puriﬁed
recombinant SUCLG1 or SUCLG2 protein has been immunodetected. Puriﬁed protein has been loaded in the
leftmost lane (30 ng) and in the adjacent right one (3 ng). In the remaining subpanels of Figure 2A–C, 30 ng of
either SUCLG1 or SUCLG2 was loaded. From the bands obtained from the puriﬁed proteins in relation to
those obtained from the puriﬁed mitochondria, we deduce that (i) the bands detected from the mitochondrial
samples corresponding to slightly lower though nearly identical molecular weight (MW) presumably due to the
hexahistidine tags of the recombinant proteins genuinely represent the sought proteins and (ii) the amount of
either SUCLG1 or SUCLG2 in 3.75 mg of puriﬁed mitochondria corresponds to between 3 and 30 ng. The anti-
body directed against SUCLA2 protein has been validated in ref. [17] using ﬁbroblasts from a patient with
SUCLA2 deletion. Anti-VDAC1 was used as a loading control.
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As shown in Figure 2A–C and from the quantiﬁcation of the band densities in relation to that of VDAC1
shown in Figure 2D–F, respectively, Sucla2+/− mice exhibited up to 76% decrease in Sucla2 expression,
depending on the tissue and the age of the mice. Concomitantly, Sucla2+/− mice exhibited up to 66% reduc-
tion in Suclg1 protein, but also up to 177% increase in Suclg2 protein.
In agreement with the above results regarding Suclg1/g2/a2 subunit quantiﬁcation, ATP-forming activity of
Sucla2+/− mice decreased, while GTP-forming activity increased, though only in heart mitochondria, for all
ages (Figure 3).
From the above experiments, we obtained the information that deletion of one Sucla2 allele is associated
with a decrease in Suclg1 expression and a rebound increase in Suclg2 expression, and this is reﬂected in recip-
rocal decrease vs. increase in ATP-forming vs. GTP-forming SUCL activity.
Figure 1. Generation of Sucla2 mutant mice and Sucla2 mRNA quantiﬁcation.
(A) Gene trap vector for generating Sucla2 mutant mice. (B) Bar graphs of qPCR of Sucla2 mRNA ratioed to β-actin mRNA of
3-, 6- and 12-month-old WT and Sucla2+/− mice from liver, heart and brain. (C) Bar graphs of qPCR of Sucla2 mRNA ratioed
to Psmc4 mRNA of 3-, 6- and 12-month-old WT and Sucla2+/− mice from liver, heart and brain. *P < 0.05, **P < 0.01 and
***P < 0.001. Data are SEM from four different organs per animal group.
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Generation of Suclg2 mutant mice and characterization of SUCL subunit
expression and enzymatic activities of WT vs. Suclg2+/− mice
Mutant Suclg2 mice were generated using a gene-trapping technique [4]. Mice (strain Albino B6) were cloned
from an ES cell line (Ayu21-KBW131; Exchangeable Gene Trap Clones: EGTC). The ES cell clone contained a
Figure 2. SUCL subunit expression in WT vs. Sucla2+/− mice.
(A–C) Scanned images of Western blotting of puriﬁed SUCLG1 and SUCLG2 and mitochondria of 3-, 6- and 12-month-old WT
and Sucla2+/− mice from liver, heart and brain. (D–F) Band density quantiﬁcation of the scanned images shown in A–C,
respectively. Data were arbitrarily normalized to the average density of the ﬁrst two bands of WT mice per organ. ***P < 0.001.
Each Western blot lane contains mitochondria (except those containing the puriﬁed SUCLG1 or SUCLG2 proteins) pooled from
two or four organs per animal group. Data shown in the bar graphs are SEM.
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trap vector insertion in the Suclg2 gene (ﬁrst intron) identiﬁed from the EGTC database and was aggregated
with morulae from ICR mice to generate germline chimaeras using standard procedures. pU21-W (accession
number: AB427140, 9333 bp) was a ‘promoter trap’ vector with three stop codons, which were arranged
upstream of the ATG of the β-geo in all three frames (see Figure 4A). Insertion of the trap vector into the
Suclg2 gene led to the splicing of the endogenous upstream exons into this cassette to produce a fusion tran-
script that leads to termination of further transcription of the endogenous Suclg2 exons downstream of the
insertion. Chimaeric males were bred to C57BL/6N females for germline transmission of the mutant Suclg2
allele. To investigate the expression level of Suclg2 mRNA of Suclg2 heterozygote, the original ES cell line
(Ayu21-KBW131: +/−) was compared with the parental strain (KAB6: +/+). mRNA was puriﬁed from parental
ES cells (+/+) and 21-KBW131 (+/−). Suclg2 expression levels of these cells were analyzed by real-time PCR
using the TaqMan Gene Expression Assays, XS, Suclg2 (AB, 4448892, FAM/MGB-NFQ) kit. Heterozygous ES
cells showed almost half the amount of Suclg2 mRNA compared with parent cells (Figure 4B).
Mitochondria were prepared from the livers, hearts and brains of 3-, 6- and 12-month-old WT and Suclg2
+/− mice, and SUCLG1, SUCLA2, SUCLG2 and VDAC1 were immunodetected by Western blotting, exactly as
described in Figure 2. Scanned images of representative Western blots are shown in Figure 5A–C. As shown in
the ﬁrst lane of the left topmost panel in Figure 5A, puriﬁed recombinant SUCLG1 or SUCLG2 protein has
been immunodetected. Puriﬁed protein has been loaded in the leftmost lane (30 ng). From the bands obtained
from the puriﬁed proteins in relation to those obtained from the puriﬁed mitochondria, we deduce that (i) the
bands detected from the mitochondrial samples corresponding to slightly lower though nearly identical MW
presumably due to the hexahistidine tags of the recombinant proteins genuinely represent the sought proteins
Figure 3. ATP- and GTP- forming SUCL activity in WT vs Sucla2+/− mice.
(A) Bar graphs of ATP-forming SUCL activity from mitochondria of 3-, 6- and 12-month-old WT (solid) and Sucla2+/− (striped)
mice from liver, heart and brain. (B) Bar graphs of GTP-forming SUCL activity from mitochondria of 3-, 6- and 12-month-old
WT and Sucla2+/− mice from liver, heart and brain. *P < 0.05, **P < 0.01. Data shown are SEM from two or four pooled organs
per animal group from four independent experiments.
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and (ii) the amount of either SUCLG1 or SUCLG2 in 3.75 mg of puriﬁed mitochondria corresponds to slightly
<30 ng. Anti-VDAC1 was used as a loading control.
As shown in Figure 5A–C and from the quantiﬁcation of the band densities in relation to that of VDAC1
shown in Figure 5D–F, respectively, Suclg2+/− mice exhibited up to 56% decrease in Suclg2 expression, a
mostly insigniﬁcant decrease in Suclg1 expression, and no rebound increase in Sucla2 expression. The variabil-
ity in the decrease in Suclg2 (and Sucla2) expression in these transgenic mouse lines probably reﬂects the ‘leaki-
ness’ of the mutant allele that could produce WT mRNAs by alternative splicing around the gene trap cassette,
as has been shown in several similar situations [22,56,61,75].
From the above experiments, we obtained the information that deletion of one Suclg2 allele was not associated
with the rebound effects as seen in the Sucla2+/− mice. Because of the lack of a rebound effect on Sucla2 expression
in Suclg2+/− mice, in conjunction with the fact that SUCLG2 deﬁciency has never been reported in humans this
transgenic strain was further investigated only regarding respiration and SLP during chemical or true anoxia.
Characterization of SUCL subunit expression and enzymatic activities of
Sucla2+/−/Suclg2+/− double heterozygote mice
Since the deletion of one Sucla2 allele led to a rebound increase in Suclg2 expression, we investigated the effect
of combined loss of one allele from each Sucla2 and Suclg2 gene. Thus, we cross-bred Sucla2+/− mice with
Suclg2+/− mice, which yielded viable Sucla2+/−/Suclg2+/− offspring. The results of Western blotting of mito-
chondria isolated from the brains, livers and hearts of 12-month-old WT vs. Sucla2+/−/Suclg2+/− mice
probing for SUCLG1, SUCLG2 and SUCLA2 (and VDAC1 as a loading control) are shown in Figure 6A (per-
formed exactly as described in Figure 2). The quantiﬁcation of the band densities in relation to that of VDAC1
is shown in Figure 6B. As shown in Figure 6B, deletion of one Sucla2 allele still yields a rebound increase in
Sucgl2 expression in liver, albeit protracted because these mice also lack one Suclg2 allele. By the same token,
the anticipated decrease (due to deletion of one Suclg2 allele) in Suclg2 expression is lost, presumably because
of the effect(s) of deletion of the Sucla2 allele, antagonizing the diminution in expression of Suclg2. These
Figure 4. Generation of Suclg2 mutant mice and Suclg2 mRNA quantiﬁcation.
(A) Gene trap vector for generating Suclg2 mutant mice (adapted from http://egtc.jp/action/access/vector_detail?
vector=pU-21W). (B) Suclg2 heterozygote ES cell line (Ayu21-KBW131: +/−) was compared with parental strain (KAB6: WT).
mRNA was puriﬁed from parental ES cells (+/+) and Suclg2 heterozygote (+/−). Suclg2 mRNA expression level was analyzed by
real-time PCR using a TaqMan probe for Suclg2 (AB, 4448892, FAM/MGB-NFQ) and normalized by a TaqMan probe for
β-actin (AB, 4448489, VIC-MGB). Asterisk signiﬁes P=0.039. Data shown are SEM from four independent experiments.
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results are also reﬂected in the measured ATP- and GTP-forming activities of WT vs. Sucla2+/−/Suclg2+/−
mice, shown in Figure 6C,D, respectively: ATP-forming activity is diminished in the double heterozygote mice,
compared with WT littermates due to loss of one Sucla2 allele; however, GTP-forming activity remains
unaffected, despite the loss of one Suclg2 allele.
From these experiments, we deduce that the effect(s) of deleting one Sucla2 allele up-regulating Suclg2
expression is so dominant that it adequately antagonizes or even supersedes the effect(s) of a concomitant loss
of one Suclg2 allele.
Figure 5. SUCL subunit expression in WT vs. Suclg2+/− mice.
(A–C) Scanned images of Western blotting of puriﬁed SUCLG1 and SUCLG2 and mitochondria of 3-, 6- and 12-month-old WT
and Suclg2+/− mice from liver, heart and brain. (D–F) Band density quantiﬁcation of the scanned images shown in A–C,
respectively. Data were arbitrarily normalized to the average density of the ﬁrst two bands of WT mice per organ. *P < 0.05,
**P < 0.01 and ***P < 0.001. Each Western blot lane contains mitochondria (except those containing the puriﬁed SUCLG1 or
SUCLG2 proteins) pooled from two or four organs per animal group. Data shown in the bar graphs are SEM.
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The effect of deleting one Sucla2 allele on mitochondrial respiration
Mitochondria were prepared from the livers, hearts and brains of 3-, 6- and 12-month-old WT and Sucla2+/−
mice and states 2 and 3 (induced by the addition of 2 mM ADP) of mitochondrial respiration were evaluated
using an array of substrates, as indicated in Figure 7. As shown in Figure 7, with the exception of one combin-
ation for state 2 respiration and ﬁve combinations for state 3 respiration, the remaining 84 combinations of
substrates per tissue of origin per age of mice did not reveal statistically signiﬁcant differences between WT and
Sucla2+/− mice.
From these experiments, we concluded that a partial decrease in Sucla2 expression did not impact negatively
on mitochondrial respiration to an appreciable extent. This lack of effect could be also explained by the
rebound increases in Suclg2 expression and associated increases in GTP-forming SUCL activity that in turn
could impact on mitochondrial ATP output through the concerted action of the nucleotide diphosphate kinase.
In addition to this, it is possible that the ﬂux control coefﬁcient of SUCL regarding mitochondrial respiration is
small enough, so that inhibition of this enzyme to the extent observed hereby in the Sucla2+/− transgenic mice
was insufﬁcient to warrant a measurable effect on mitochondrial respiration.
Figure 6. Characterization of SUCL subunit expression of Sucla2+/−/Suclg2+/− mice (dht: double heterozygote) and
SUCL enzymatic activities.
(A) Scanned images of Western blotting of 12-month-old WT and Sucla2+/− / Suclg2+/− mice from liver, heart and brain.
(B) Band density quantiﬁcation of the scanned images shown in A. Data were arbitrarily normalized to the average density of
the ﬁrst two bands of WT mice per organ. *P < 0.05, **P < 0.01 and ***P < 0.001. Each Western blot lane contains mitochondria
pooled from two or four organs per animal group. Data shown in the bar graph are SEM. (C) Bar graphs of ATP-forming SUCL
activity from mitochondria of 12-month-old WT (solid) and Sucla2+/−/Suclg2+/− (double-striped) mice from liver. (D) Bar
graphs of GTP-forming SUCL activity from mitochondria of 12-month-old WT (solid) and Sucla2+/−/Suclg2+/− (double-striped)
mice from liver. Data shown in C and D are SEM from two or four pooled organs per group from four independent
experiments.
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Figure 7. Bar graphs of measurements of oxygen consumption in the medium containing isolated mitochondria of 3-,
6- and 12-month-old WT (solid) and Sucla2+/− (striped) mice from liver, heart and brain.
Substrate combinations used as indicated in the panels, all at concentration of 5 mM, except β-hydroxybutyrate (β-OH) that
was 4 mM. St2: state 2 respiration; St3: state 3 respiration. *P < 0.05, **P < 0.01 and ***P < 0.001. Data shown are SEM from
two or four pooled organs per animal group from four independent experiments.
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The effect of deleting one Sucla2 allele on ΔΨm and SLP during inhibition of
complex I by rotenone or true anoxia
In the absence of oxygen or when the electron transport chain is impaired, SLP in the matrix substantiated by
the reaction catalyzed by SUCL is the only means for production of high-energy phosphates in mitochondria.
When the electron transport chain is compromised and F0–F1 ATP synthase reverses pumping protons out of
the matrix at the expense of ATP hydrolysis, the mitochondrial membrane potential is maintained — albeit at
decreased levels — for as long as matrix SLP is operational, without a concomitant reversal of the adenine
nucleotide translocase (ANT), thus preventing mitochondria from becoming ATP consumers [9,10,12,13].
Mitochondrial SLP can be assessed by recording the directionality of the ANT during respiratory inhibition.
The latter can be achieved either pharmacologically (i.e. by inhibiting complex I with rotenone) or with anoxia.
The assessment of the directionality of the ANT can be performed by a ‘biosensor test’ developed in our
laboratory [13]. This test is based on the concept that one molecule of ATP4− is exchanged for one molecule of
ADP3− (both nucleotides being Mg2+-free and deprotonated) by the ANT [37]. Therefore, during forward
mode of the ANT (ATP moving outward from mitochondria in exchange of an inward movement of one
ADP), abolition of its operation by a speciﬁc inhibitor such as cATR leads to an increase in ΔΨm, whereas
during the reverse mode of ANT, cATR leads to a loss of ΔΨm.
In this work, we evaluated matrix SLP during either inhibition of complex I by rotenone or during anoxia.
Mitochondria were prepared from the livers, hearts and brains of 3-, 6-, and 12-month-old WT (black traces)
and Sucla2+/− (red traces) mice, and ΔΨm was evaluated using an array of substrates, indicated in
Supplementary Material.
Time-lapse recordings of safranin O ﬂuorescence reﬂecting ΔΨm (while measuring oxygen concentration in
the same sample) were achieved by using the recently developed O2k-Fluorescence LED2-Module of the
Oxygraph-2k (Oroboros Instruments, Innsbruck, Austria). Mitochondria were allowed to deplete the oxygen
dissolved in the air-sealed chamber and additions of chemicals through a tiny-bore hole did not allow
re-oxygenation of the buffer from the ambient atmosphere. The sequences of additions were as follows: mito-
chondria were added in 2 ml of buffer (see ‘Experimental Procedures’) containing substrates as indicated in the
panels and allowed to fully polarize (solid traces). State 3 respiration was initiated by ADP (2 mM) depolarizing
mitochondria; within a few minutes (depending on the substrates), mitochondria became anoxic as veriﬁed by
recording ‘zero’ levels of dissolved oxygen in the chamber (dotted traces). Anoxia also coincided with the onset
of an additional depolarization leading to a clamp of ΔΨm. The subsequent addition of cATR (1 mM) caused
either a moderate re- or de-polarization, implying that the ANT was operating in the forward or reverse mode,
respectively. Further addition of the uncoupler SF 6847 (1 mM) was subsequently used to cause a complete col-
lapse of ΔΨm and assist in the calibration of the ﬂuorescence signal. As shown in Supplementary Figures S1A–
C and S2C,D, there were no differences between mitochondria from WT and Sucla2+/− mice. Likewise, when
SLP was examined during inhibition of the respiratory chain by rotenone instead of anoxia, no differences
between WT and Sucla2+/− mice mitochondria were observed (Supplementary Figures S2A,B and S3A–C).
Similar to the results obtained from mitochondrial respiration, the lack of effect could be also explained by the
rebound increases in Suclg2 expression and associated increases in GTP-forming SUCL activity that in turn
could affect mitochondrial ATP output through the concerted action of the nucleotide diphosphate kinase (see
above), or, as mentioned above, it is possible that the ﬂux control coefﬁcient of SUCL regarding mitochondrial
respiration is small enough, so that inhibition of this enzyme to the extent observed hereby in the Sucla2+/−
transgenic mice was insufﬁcient to warrant a measurable effect. By the same token, no differences in mitochon-
drial respiration or SLP during chemical or true anoxia were observed by comparing Suclg2+/− vs. WT litter-
mate mice (Supplementary Figures S4–S6). By comparing WT vs. Sucla2+/−/Suclg2+/− double heterozygote
mice, we also observed no difference in the ability of SLP to maintain ANT in the forward mode, with the
exception of using glutamate + malate + β-hydroxybutyrate as substrates (a substrate combination that does not
favor SLP) in liver mitochondria, where we obtained the full spectrum of results, ranging from maintenance of
SLP to its abolition (Supplementary Figure S7). However, a concomitant submaximal inhibition of SUCL by
KM4549SC or itaconate [51] revealed that mitochondria obtained from Sucla2+/− mice are less able to
perform SLP (Figure 8A,B and Supplementary Figures S8–S10). The argument that SUCLA2 is critical for SLP
is also strengthened by the ﬁndings where, by applying the ‘biosensor test’ in permeabilized ﬁbroblasts from a
control subject vs. a patient suffering from complete deletion of SUCLA2 [47], the in situ mitochondria from
the patient are unable to perform SLP during respiratory inhibition by rotenone (Figure 8C).
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The effect of deleting one Sucla2 allele on ETC/CS
Mindful that some patients suffering from SUCLA2 deﬁciency exhibited decreases in the activities of electron
transport chain complexes, we investigated the effect of deleting one Sucla2 allele in mice on complex I, II, II/
III and IV activities, ratioed to citrate synthase activity. As shown in Figure 9, mitochondria from all tissues
and all ages revealed no statistically signiﬁcant differences between WT and Sucla2+/ mice. However, by com-
paring WT vs. Sucla2+/−/Suclg2+/− double heterozygote mice, there was a statistically signiﬁcant increase in
succinate dehydrogenase activity in heart mitochondria, echoing the results of Donti et al. [18] in Sucla2−/−
mouse embryonic ﬁbroblasts.
The effect of deleting one Sucla2 allele on mtDNA
Because of the involvement of SUCL in the maintenance of mtDNA, we compared the amount of mtDNA in
the tissues of WT vs. Sucla2+/− mice. As shown in Figure 10, relative mtDNA content from the livers, hearts
Figure 8. Reconstructed time courses of safranin O signal calibrated to ΔΨm (solid traces), and parallel measurements
of oxygen concentration in the medium (dotted traces) in mitochondria of 3- and 12-month-old WT (black) and Sucla2+/−
(red) mice isolated from liver, in the presence of (A) 400 nM KM4549SC or (B) itaconate (2.5 mM).
ADP: 2 mM; cATR, 1 mM. Substrate concentrations were glutamate (5 mM) and malate (5 mM). At the end of each experiment,
1 mM SF 6847 was added to achieve complete depolarization. (C) Reconstructed time course of safranin O signal from
permeabilized ﬁbroblasts of a control subject (black dots) and a patient suffering from complete SUCLA2 deletion (green dots).
Rot: rotenone, 1 mM. Data shown are representative of at least four independent experiments.
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and brains of 3-, 6- and 12-month-old mice was quantitated by real-time PCR. It is evident that there is a mod-
erate but statistically signiﬁcant decrease in mtDNA in all tissues of 3-month-old mice and in the brains of
12-month-old mice. Furthermore, by comparing WT vs. Sucla2+/−/Suclg2+/− double heterozygote mice, there
was a much greater statistically signiﬁcant decrease in mtDNA in the livers and brains of double heterozygote
mice, compared with WT littermates.
The effect of deleting one Sucla2 allele on blood carnitine esters
Finally, in view of the association of SUCL activity with the catabolism of a particular group of biomolecules
converging to succinyl-CoA through propionyl-CoA and methylmalonyl-CoA which are in equilibrium with
their carnitine esters, we measured the levels of 20 carnitine esters in the blood of mice. As shown in Figure 11,
there are statistically signiﬁcant increases in 36 out of 63 comparisons of carnitine esters in the blood of Sucla2+/−
Figure 9. Bar graphs of measurements of complex I, II, II + III and IV activities (ETC) ratioed to CS activity in
isolated mitochondria of 3-, 6- and 12-month-old WT (solid), Sucla2+/− (striped) mice from liver, heart and brain, and
Sucla2+/−/Suclg2+/− (double-striped) mice from livers of 12-month-old mice.
*P < 0.05. Data shown are SEM from two or four pooled organs per animal group from four independent experiments.
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Figure 10. Bar graphs of relative measurements of mtDNA content of livers, hearts and brains from 3-, 6- and
12-month-old WT (solid) compared with that from Sucla2+/− (striped) mice, and Sucla2+/−/Suclg2+/− (double-striped)
mice from livers of 12-month-old mice.
**P < 0.01 and ***P < 0.001. Data shown are SD from four pooled organs per animal group from four independent experiments.
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Figure 11. Bar graphs of measurements of carnitine and its esters in the blood of 3-, 6- and 12-month-old WT (solid)
and Sucla2+/− (striped) mice and Sucla2+/−/Suclg2+/− (double-striped) from 12-month-old mice.
*P < 0.05, **P < 0.01 and ***P < 0.001. Data shown are SEM from four blood draws per animal group from four mice each.
Carnitine (free); C2(acetyl); C3 (propionyl); C4 (butyryl/isobutyryl); C5 (isovaleryl/2-methylbutyryl/pivaloyl); C4-OH
(3-hydroxybutyryl); C5-OH (3-hydroxy isovaleryl/2-methyl 3-hydroxybutyryl); C3-DC (malonyl); C10:1 (decenoyl); C10
(decanoyl); C4-DC (methylmalonyl/succinyl); C5-DC (glutaryl); C12 (C6-1DS, dodecanoyl); C14:1 (tetradecenoyl); C14
(myristoyl); C16 (palmitoyl; C16-OH (3-hydroxyhexadecenoyl); C18:1 (oleyl); C18 (stearoyl); C18-OH (3-hydroxystearoyl).
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mice from all age groups compared with that from WT mice, but also 6 occasions in which carnitine esters of
Sucla2+/− mice is decreased compared with those of WT mice. What is also noteworthy is that although
SUCLA2 deﬁciency in humans is associated with elevations of C3 and C4-DC levels, in the Sucla2+/− mice
there was elevation of several additional esters including those encompassing long-chain fatty acid chains
(C16-OH, C18:1, C:18 and C18-OH). This may be due to a plausible ‘CoASH trap’ in the form of
succinyl-CoA, depleting mitochondria from CoASH which is critical for the entry and catabolism of long-chain
fatty acids in mitochondria. Indeed, as seen in oxygen consumption experiments (Figure 7) when using
α-ketoglutarate (α-Kg) as a substrate, heart mitochondria (which are dependent on CoASH for optimal catabol-
ism of fatty acids) of Sucla2+/− mice exhibited smaller state 2 and state 3 respiration rates than WT mice,
implying that KGDHC activity may be impaired, possibly due to insufﬁcient amounts of CoASH. Furthermore,
by comparing WT vs. Sucla2+/−/Suclg2+/− double heterozygote mice, there was a greater statistically signiﬁ-
cant increase in some carnitine esters of the blood of double heterozygote mice, compared with WT
littermates.
Discussion
Mitochondrial diseases are collectively considered as a major cause of encephalomyopathies and other multisys-
tem maladies [19,62,63]. A considerable fraction of this pool of diseases encompasses mtDNA depletion [23].
Many animal models have been generated to model mtDNA depletion by speciﬁcally deleting genes important
for mtDNA replication [2,25,27,34,43,45,73,74], although only one study has addressed the role of SUCL [18].
In the latter work by Donti et al., tissues from Sucla2−/− mice were examined at an embryonic stage, because —
like in our study— no viable homozygote offsprings were born. Nevertheless, accordance to a large extent is
observed between the results obtained by Donti et al. and our study, despite embryonic tissues of Sucla2−/−
mice being examined as opposed to here where we investigated tissues from Sucla2+/− heterozygote adult
mice, those engineered to lack one Suclg2 allele, as well as Sucla2+/−/Suclg2+/− double heterozygotes. Among
the striking similarities are the varying degrees of mtDNA alterations, the reciprocal increase in Suclg2 expres-
sion when Sucla2 levels are decreased, elevations in methylmalonyl esters and a mild increase in succinate
dehydrogenase activity. However, unlike in Donti et al. [18], we did not observe alterations in the activities of
other than complex II ETC components, or any changes in mitochondrial respiration, or SLP.
In more detail, the most important results of the present work are those obtained by the comparisons of WT
with Sucla2+/− mice. These can be categorized to: (i) rebound increase in Suclg2 expression and associated
GTP-forming activity; (ii) lack of effect on bioenergetic parameters including SLP; (iii) moderate mtDNA
decrease and (iv) elevation of short- and long-chain carnitine esters in the blood of heterozygote mice. It is
important to emphasize that the rebound increase in Suclg2 expression in Sucla2+/− mice seemed to occur
mostly in heart mitochondria, also in brain mitochondria but only from the older (6–12 months old) mice and
not in liver mitochondria. Furthermore, the increase in GTP-forming activity also seemed heart-speciﬁc, as
well as the changes in complex II activity observed in Sucla2+/−/Suclg2+/− mice. Obviously, the molecular
mechanisms responsible for these rebound effects are tissue-speciﬁc and appear to be operational in the heart
and at least some brain-speciﬁc cells, but not in the liver. The elucidation of such molecular mechanisms may
be of great value in setting an example of gene–gene interactions of similar nature.
On the same line, regarding the rebound increase in Suclg2 expression and associated GTP-forming activity
in Sucla2 heterozygote mice, the concept of ‘complementation’ between Sucla2 and Suclg2 and —as an exten-
sion of this— ATP- and GTP-forming activity has been proposed earlier [47]. As mentioned above, this has
been observed in embryonic tissues of Sucla2−/− mice [18], but not in ﬁbroblasts from patients exhibiting
mutations in SUCLA2 [47]. However, as is evident from our results, this complementation is sufﬁcient to allevi-
ate only some of the biochemical abnormalities of the Sucla2 heterozygous mice. Indeed, mitochondrial respir-
ation, ΔΨm, ETC/CS activities and SLP were virtually identical between WT and Sucla2+/− mice, while there
was mild mtDNA depletion but signiﬁcant alterations in blood carnitine esters. The alterations in mtDNA
should be attributed to alterations in the activity of SUCL with caution; it has been recently reported that
GABA transaminase is essential for mitochondrial nucleoside metabolism and thus is important for mtDNA
maintenance, and it co-immunoprecipitates with SUCLG1, SUCLG2 and SUCLA2 [5]. The alterations in the
carnitine esters concern those with both short- and long-chain. However, the levels of free carnitine in four het-
erozygous human carriers for SUCLA2 mutations were not signiﬁcantly elevated, compared with reference
values (values were 25, 27, 29 and 37, with reference values of 24–64 mmol/l).
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Finally, regarding the rebound increase in Suclg2 expression in Sucla2+/− mice, it is noteworthy to empha-
size that the concomitant loss of one Suclg2 allele yielding Sucla2+/−/Suclg2+/− double transgenic mice was
not sufﬁcient to impose a considerable decrease in Suclg2 expression or GTP-forming SUCL activity.
Apparently, the translational or posttranslational mechanism(s) mediating this effect (as there was no change
in Suclg2 transcript, reported in ref. [18]) supersede those occurring at the gene level and merit further
consideration.
In aggregate, we proﬁled the metabolism of two transgenic mouse models for β-subunit components of
SUCL; the results presented and the availability of these transgenic mouse colonies to the scientiﬁc community
are of value in the pursuit for understanding SUCL deﬁciency.
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